Key result
New anticoagulants, including direct thrombin and factor Xa inhibitors, are under development and offer significant advantages over currently available options like warfarin and heparin.
Emerging anticoagulants, including direct thrombin and factor Xa inhibitors, promise significant clinical advantages over traditional therapies like warfarin by offering easier dosing and fewer interactions.
Authors
No takes yet. Share an insight, caveat, or question.
Should not yet change anticoagulation practice in vascular surgery; leaves open comparative efficacy of direct thrombin and factor Xa inhibitors.
Stone et al. (2007) conducted a review in Thromboembolic events. New anticoagulants (meta-pentasaccharides, direct thrombin inhibitors, direct X inhibitors) vs. Warfarin, heparin compounds was evaluated. New anticoagulants, including direct thrombin and factor Xa inhibitors, are under development and offer significant advantages over currently available options like warfarin and heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: